These payloads cut off a supply route for a molecule cells need to keep their metabolism working. Antibody delivery is being studied to direct that effect toward tumors.
NAMPT inhibitors interfere with nicotinamide adenine dinucleotide, or NAD, salvage. Anti-c-KIT conjugates showed target-dependent efficacy in a gastrointestinal stromal tumor xenograft study. A later primary study examined physicochemical and metabolic optimization of NAMPT inhibitor conjugates for blood and solid tumor models. These are preclinical payload studies; the dependence of healthy tissues on NAD makes selective delivery and tolerability central questions.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/